Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AXA    CS   FR0000120628

AXA

(CS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AXA : First signs of a reversal

share with twitter share with LinkedIn share with facebook
share via e-mail
07/11/2019 | 04:53am EDT
short sell
Live
Entry price : 23.62€ | Target : 22.6€ | Stop-loss : 24.2€ | Potential : 4.32%
Shares in AXA reflect a technical chart that has deteriorated, suggesting that the beginning of a tendency reversal is near, which could lead to a somewhat longer downward-trading phase.
Investors should open a short trade and target the € 22.6.
Chart AXA
Duration : Period :
AXA Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The stock, which is currently worth 2019 to 0.5 times its sales, is clearly overvalued in comparison with peers.
  • Its low valuation, with P/E ratio at 8.81 and 8.06 for the ongoing fiscal year and 2020 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 21.13 EUR

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at EUR 23.8.
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Life & Health Insurance - NEC
1st jan.Capitalisation (M$)Investor Rating
AXA24.75%62 795
PRUDENTIAL PLC22.36%55 510
METLIFE21.09%47 252
PRUDENTIAL FINANCIAL23.87%41 014
AFLAC20.72%41 001
MANULIFE FINANCIAL CORP.25.56%36 501
ASSICURAZIONI GENERALI15.75%29 759
SUN LIFE FINANCIAL INC22.23%25 022
NEW CHINA LIFE INSURANCE CO..28.31%21 524
-
GREAT-WEST LIFECO INC5.36%21 072
AVIVA11.80%20 556
Autres valeurs du secteur

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 108 B
EBIT 2019 7 717 M
Net income 2019 6 048 M
Finance 2019 7 706 M
Yield 2019 6,24%
P/E ratio 2019 8,79x
P/E ratio 2020 8,01x
EV / Sales2019 0,44x
EV / Sales2020 0,44x
Capitalization 55 832 M
Upcoming event on AXA
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 27,38  €
Last Close Price 23,53  €
Spread / Highest target 36,0%
Spread / Average Target 16,4%
Spread / Lowest Target -6,48%
EPS Revisions
Managers
NameTitle
Thomas Buberl Chief Executive Officer & Director
Denis Pierre Marie Duverne Chairman
Astrid Stange Chief Operating Officer
Gérald Harlin Group Chief Financial Officer
François Martineau Independent Director